Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?-Reference-Cited by-同舟云学术

Should Rituximab be Considered as the First-Choice Treatment for Severe Autoimmune Rheumatic Diseases?

Published:2007-09-22 Issue:1 Volume:34 Page:124-128
ISSN:1080-0549
Container-title:Clinical Reviews in Allergy & Immunology
language:en
Short-container-title:Clinic Rev Allerg Immunol

Author:

Galarza Claudio,Valencia Diana,Tobón Gabriel J.,Zurita Luis,Mantilla Rubén D.,Pineda-Tamayo Ricardo,Rojas-Villarraga Adriana,Rueda Juan C.,Anaya Juan-Manuel

Publisher

Springer Science and Business Media LLC

Subject

General Medicine,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1007/s12016-007-8028-z.pdf

Reference38 articles.

1. Youinou P et al (2006) B lymphocytes on the front line of autoimmunity. Autoimmun Rev 5:215–221

2. Reff ME et al (1994) Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 83:435–445

3. Shan D, Ledbetter JA, Press OW (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells. Cancer Immunol Immunother 48:673–683

4. Einfeld DA et al (1988) Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains. EMBO J 7:711–717

5. Valentine MA et al (1989) Phosphorylation of the CD20 phosphoprotein in resting B lymphocytes. Regulation by protein kinase C. J Biol Chem 264:11282–11287

Cited by 77 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Bronquiectasias, adenopatías relacionadas con la sobreexpresión del factor activador de los linfocitos B perteneciente a la familia del factor de necrosis tumoral y cistitis linfoplasmocítica como eventos adversos asociados al uso prolongado de rituximab en enfermedades reumáticas autoinmunes sistémicas;Revista Clínica Española;2024-08

2. Bronchiectasis, lymphadenopathies related to BAFF overexpression and lymphoplasmacytic cystitis as adverse events associated with prolonged use of rituximab in systemic autoimmune rheumatic diseases;Revista Clínica Española (English Edition);2024-08

3. A Glimpse into Humoral Response and Related Therapeutic Approaches of Takayasu’s Arteritis;International Journal of Molecular Sciences;2024-06-13

4. Effectiveness and safety of rituximab in Takayasu arteritis: a multicenter retrospective study;Joint Bone Spine;2024-03

5. Modern approaches to the treatment of Takayasu arteritis;Modern Rheumatology Journal;2024-02-21